Skip to content
DraconiticResearch
Search Sources API
181,716 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BYRedox report : communications in free radical research

From ER and mitochondria to contact sites: integrated regulation of ferroptosis in cardiovascular diseases.

  1. 1IRCCS Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
  2. 2Department of Biosciences, Biotechnologies and Environment, University of Bari "A. Moro", Bari, Italy.
  3. 3Department of Medical Sciences, Section of Experimental Medicine and Technopole of Ferrara, Laboratory for Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy.

Abstract

Iron is a central regulator of cellular redox homeostasis, supporting essential physiological processes. Given its critical biological importance, iron homeostasis is tightly regulated at both the systemic and cellular levels. Ferroptosis is a metabolically regulated, iron-dependent form of cell death characterized by the accumulation of phospholipid hydroperoxides driven by iron-catalyzed redox reactions, ultimately leading to oxidative membrane damage. Accumulating evidence indicates that ferroptosis emerges from the coordinated activity of multiple subcellular organelles rather than from isolated pathways. In this context, the endoplasmic reticulum (ER) and mitochondria have recently been established as key regulators of ferroptotic signaling. Notably, mitochondria-associated membranes (MAMs), by spatially coordinating redox signaling and lipid peroxidation, calcium fluxes, mitochondrial metabolism and lipid remodeling, are increasingly recognized as central hubs within the ferroptotic cascade, acting as modulators of cellular susceptibility to ferroptosis and as key sites of its execution. Owing to its strong dependence on mitochondrial oxidative phosphorylation, the heart is particularly sensitive to perturbations in iron homeostasis. Notably, growing evidence supports a pathogenic role for ferroptosis in cardiovascular diseases (CVDs), linking iron-dependent oxidative stress to cardiomyocyte dysfunction and tissue injury. Accordingly, ferroptosis has emerged as a potential therapeutic target in cardiovascular pathology. This review examines how ER and mitochondrial dysfunction contribute to ferroptotic signaling in CVDs and discusses the hypothesis that MAMs may function as central regulatory interfaces coordinating these processes. Elucidating these mechanisms is essential for the development of novel therapeutic strategies aimed at modulating ferroptosis and limiting CVDs progression.

Related

  1. From mitochondrial injury to organelle communication: a bibliometric analysis of mitochondria-associated membranes research in cardiovascular diseases
    Peng Li, Yan-ting Pang, Yuxuan Li +3
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  2. Long-chain acyl-CoA synthetases in female reproductive diseases: isoform-specific regulation of lipid metabolism, ferroptosis, and inflammatory signaling
    Shanyuan Jin, Lin Guo, Zishuo Wu +4
    Frontiers in EndocrinologyPeer-reviewedCC BY 4.0OncologyCrossref
  3. Mitochondria-associated ferroptosis in ischemic stroke: Pathophysiological evolution, interorganelle crosstalk, and therapeutic targeting
    Mengge Zhang, Yuzhe Cai, Qianru Zeng +7
    Pharmacological ResearchPeer-reviewedCC BYFull textPharmacology & toxicologyDOAJ
  4. ANO6 Scaffolds ER Mitochondria Contacts to Govern Spatial Lipid Compartmentalization and Ferroptosis Evasion in Chemoresistant Breast Cancer
    Q. Yang, J. Yan, P. Zhao +5
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  5. Protecting Neurons in Retinal and Optic Nerve Diseases: The Role of Ferroptosis-Associated Pathways
    Lu Xiang, Xiaoyuan Ye, Amy Cheuk Yin Lo
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General medicineCrossref
BibTeX
@article{leo2026from,
  title = {{From ER and mitochondria to contact sites: integrated regulation of ferroptosis in cardiovascular diseases.}},
  author = {Sara Leo and Fabio Mollica and Gaia Pedriali and Giampaolo Morciano and Elena Nicoletta Colarusso and Elena Tremoli and Paolo Pinton},
  journal = {Redox report : communications in free radical research},
  year = {2026},
  month = nov,
  doi = {10.1080/13510002.2026.2732768},
  url = {https://europepmc.org/article/MED/42967865},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - From ER and mitochondria to contact sites: integrated regulation of ferroptosis in cardiovascular diseases.
AU  - Sara Leo
AU  - Fabio Mollica
AU  - Gaia Pedriali
AU  - Giampaolo Morciano
AU  - Elena Nicoletta Colarusso
AU  - Elena Tremoli
AU  - Paolo Pinton
PY  - 2026
DA  - 2026/11/01
JO  - Redox report : communications in free radical research
DO  - 10.1080/13510002.2026.2732768
UR  - https://europepmc.org/article/MED/42967865
AB  - Iron is a central regulator of cellular redox homeostasis, supporting essential physiological processes. Given its critical biological importance, iron homeostasis is tightly regulated at both the systemic and cellular levels. Ferroptosis is a metabolically regulated, iron-dependent form of cell death characterized by the accumulation of phospholipid hydroperoxides driven by iron-catalyzed redox reactions, ultimately leading to oxidative membrane damage. Accumulating evidence indicates that ferroptosis emerges from the coordinated activity of multiple subcellular organelles rather than from isolated pathways. In this context, the endoplasmic reticulum (ER) and mitochondria have recently been established as key regulators of ferroptotic signaling. Notably, mitochondria-associated membranes (MAMs), by spatially coordinating redox signaling and lipid peroxidation, calcium fluxes, mitochondrial metabolism and lipid remodeling, are increasingly recognized as central hubs within the ferroptotic cascade, acting as modulators of cellular susceptibility to ferroptosis and as key sites of its execution. Owing to its strong dependence on mitochondrial oxidative phosphorylation, the heart is particularly sensitive to perturbations in iron homeostasis. Notably, growing evidence supports a pathogenic role for ferroptosis in cardiovascular diseases (CVDs), linking iron-dependent oxidative stress to cardiomyocyte dysfunction and tissue injury. Accordingly, ferroptosis has emerged as a potential therapeutic target in cardiovascular pathology. This review examines how ER and mitochondrial dysfunction contribute to ferroptotic signaling in CVDs and discusses the hypothesis that MAMs may function as central regulatory interfaces coordinating these processes. Elucidating these mechanisms is essential for the development of novel therapeutic strategies aimed at modulating ferroptosis and limiting CVDs progression.
SN  - 1351-0002
SN  - 1743-2928
ER  -